<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Exicure, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Exicure, Inc.

    Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      David A. Giljohann
    • FOUNDED
      2009
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Avenue Therapeutics, Inc.

    Avenue Therapeutics, Inc.

    Avenue Therapeutics, Inc., a Fortress Biotech (NASDAQ: FBIO) Company, is a special...

    Avenue Therapeutics, Inc., a Fortress Biotech (...

    Filing Type:    PU
    Kerluxe, Inc.

    Kerluxe, Inc.

    The Kerluxe brand philosophy is to employ innovation synonymous with Swiss skincar...

    The Kerluxe brand philosophy is to employ innov...

    Fundraising Status:    EC
    Filing Type:    RA
    Karyopharm Therapeutics Inc.

    Karyopharm Therapeutics Inc.

    Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on ...

    Karyopharm Therapeutics is an innovation-driven...

    Filing Type:    PU
    Oncolytics Biotech Inc.

    Oncolytics Biotech Inc.

    Oncolytics is focused on obtaining regulatory approval for pelareorep for metastat...

    Oncolytics is focused on obtaining regulatory a...

    Filing Type:    PU
    Heron Therapeutics, Inc.

    Heron Therapeutics, Inc.

    Our mission is to improve the lives of patients by developing novel, best-in-class...

    Our mission is to improve the lives of patients...

    Filing Type:    PU
    Neon Therapeutics, Inc.

    Neon Therapeutics, Inc.

    Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field...

    Neon Therapeutics is a clinical-stage immuno-on...

    Filing Type:    PU
    Immutep Limited

    Immutep Limited

    We are a biotechnology company developing novel immunotherapy treatments for cance...

    We are a biotechnology company developing novel...

    Filing Type:    PU
    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    SELLAS Life Sciences Group, Inc.

    SELLAS Life Sciences Group, Inc.

    SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused...

    SELLAS Life Sciences Group, Inc. is a late-stag...

    Filing Type:    PU
    Forward Pharma A/S

    Forward Pharma A/S

    Forward Pharma A/S is a Danish biopharmaceutical company that commenced developmen...

    Forward Pharma A/S is a Danish biopharmaceutica...

    Filing Type:    PU
    Phormed Inc

    Phormed Inc

    PhorMed is a clinical stage biopharmaceutical company located in Beverly Hills Cal...

    PhorMed is a clinical stage biopharmaceutical c...

    Amount Raised:    $128,700.00
    Fundraising Status:    EC
    Filing Type:    CF
    Dynavax Technologies Corporation

    Dynavax Technologies Corporation

    Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...

    Dynavax Technologies Corporation (Nasdaq: DVAX)...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.